Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-EPI Study: Low-dose epinephrine in out-of-hospital cardiac arrest
2023-505349-26-00Phase 3Authorised
- Sponsor
- CHRU Nancy
- Start
- Oct 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of epinephrine in cardiac arrest (SCA) (2 arms), sponsored by CHRU Nancy. Primary endpoint: 28-day survival with favorable neurological function. Planned start Oct 2025; status: authorised.
02
Drugs
epinephrine
03
Conditions
cardiac arrest (SCA)
Beyond the preview
Go deeper on 2023-505349-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505349-26-00.